Genmab has received conditional marketing authorisation from the European Commission (EC) for TEPKINLY (epcoritamab) as a monotherapy to treat adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) following two or more lines of systemic therapy.

It is the first and only subcutaneous T-cell-engaging bispecific antibody that has gained approval to treat these patients in the EU, Iceland, Liechtenstein and Norway.

The IgG1-bispecific antibody epcoritamab has been created utilising the company’s DuoBody technology, which selectively directs cytotoxic T-cells to evoke an immune response towards target cell types.

It induces T-cell mediated killing of CD20+ cells by simultaneously binding to CD3 on T-cells and CD20 on B-cells.

The approval was based on data from the pivotal EPCORE NHL-1 Phase I/II multi-cohort, multi-centre, single-arm, open-label study.

It was designed to assess the safety and preliminary efficacy of TEPKINLY in patients with R/R large B-cell lymphoma (LBCL), including its subtype DLBCL.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

DLBCL patients who received treatment with TEPKINLY attained an overall response rate of 62% and a complete response rate of 39% with a median duration of response of 15.5 months.

TEPKINLY showed a manageable safety profile across the LBCL patient cohort, which included patients with DLBCL.

Genmab CEO Jan van de Winkel stated: “With TEPKINLY, people in Europe living with relapsed or refractory diffuse large B-cell lymphoma who are in need of additional treatment options now have a readily available, innovative therapeutic option for this aggressive cancer.”